2 completed, 1 not yet recruiting, 1 recruiting, 1 unknown. 6 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 2, Not yet recruiting 1, Recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 1 | 1 | Recruiting 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Sleep-disordered Breathing: new trials by email Literature Review of Sleep-disordered Breathing trials Research Report on Sleep-disordered Breathing
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Supplemental Oxygen for Sleep-Disordered Breathing in Adults With Chronic Opioid Use. Sham Air, Supplemental Oxygen - Sleep-disordered Breathing, Chronic Opioid Use | Phase 2 | Not yet recruiting | University of California, San Diego | 62 | 2026-12-01 | 2026-11-06 |
| Combination Upper-Airway Electrical and Pharmacological Stimulation for Obstructive Sleep Apnea Combination device and drug: Unilateral hypoglossal nerve stimulation & atomoxetine-plus-oxybutynin (HGNS+AtoOxy), Unilateral hypoglossal nerve stimulation (HGNS), active comparator condition, Atomoxetine-plus-oxybutynin (80/5 mg) (AtoOxy), active comparator condition - Obstructive Sleep Apnea, Sleep-disordered Breathing | Phase 1 / Phase 2 | Recruiting | Brigham and Women's Hospital | 24 | 2026-09-01 | 2026-09-21 |
| Managing Opioid Related Sleep Apnea With Acetazolamide Acetazolamide, Placebo - Sleep-Disordered Breathing, Obstructive Sleep Apnea | Phase 2 | Completed | University of California, San Diego | 39 | 2023-10-18 | 2026-03-10 |
| SMILES: Study of Montelukast in Sickle Cell Disease Montelukast, Oral Placebo - Anemia, Sickle Cell, Sleep-Disordered Breathing | Phase 2 / Phase 3 | Unknown | Great Ormond Street Hospital for Children NHS Foundation Trust | 200 | 2023-10-16 | 2023-11-01 |
| A Short Term Open, Randomized Cross-over Trial Exploring the Effect of Carbonic Anhydrase Inhibition by Acetazolamide on Sleep Apnea Associated Hypertension and Vascular Dysfunction Acetazolamide, nasal Continuous Positive Airway Pressure (nCPAP) - Obstructive Sleep Apnea, Sleep-Disordered Breathing | Phase 2 | Completed | Göteborg University | 13 | 2014-03-01 | 2016-08-16 |
| Effect of NT 201 (Botulinum Neurotoxin Type A Free of Complexing Proteins) on Sleep-related Breathing Disorders NT 201, a Botulinum neurotoxin type A, free of complexing proteins - Sleep-Disordered Breathing | Phase 2 | Withdrawn | Merz Pharmaceuticals GmbH | 2010-03-01 | 2015-03-30 |
Sleep Apnea Syndromes (6) · Sleep Apnea, Obstructive (4) · Sleep Apnea, Central (2) · Anemia, Sickle Cell (1) · Apnea (1) · Chronic Pain (1) · Hypertension (1) · Respiration Disorders (1) · Sleep Wake Disorders (1) · Snoring (1)
Dyssomnias (6) · Nervous System Diseases (6) · Respiratory Tract Diseases (6) · Sleep Disorders, Intrinsic (6) · Apnea (5) · Respiration Disorders (5) · Sleep Wake Disorders (5) · Pathological Conditions, Signs and Symptoms (3) · Signs and Symptoms (3) · Neurologic Manifestations (2) · Signs and Symptoms, Respiratory (2) · Anemia (1) · Anemia, Hemolytic (1) · Anemia, Hemolytic, Congenital (1) · Cardiovascular Diseases (1)
Acetazolamide (2) · Botulinum Toxins, Type A (1) · Continuous Positive Airway Pressure (1) · incobotulinumtoxinA (1) · montelukast (1)
University of California, San Diego (2) · Brigham and Women's Hospital (1) · Great Ormond Street Hospital for Children NHS Foundation Trust (1) · Göteborg University (1) · Merz Pharmaceuticals GmbH (1)
United States (3) · Sweden (1) · United Kingdom (1)
Jeremy Orr, MD (2) · Fenella Kirkham, MA MB Bchir (1) · Jan Hedner, MD. Prof. (1) · Scott A Sands, PhD (1)
K23HL151880 (1), R01HL179220 (1)